Michael W Ernest

US Patent:

20020081750, Jun 27, 2002

Filed:

Sep 20, 2001

Appl. No.:

09/956094

Inventors:

Michael Ernest - Rancho Santa Fe CA, US
Doris Slate - Rancho Santa Fe CA, US

International Classification:

C12Q001/68
G01N033/53
G01N033/50
G01N033/543
G06F019/00

US Classification:

436/518000, 435/007100, 435/006000, 702/019000, 702/020000

Abstract:

The present invention relates to methods for determining whether a drug candidate should be advanced from discovery through evaluation to development and marketing. In one embodiment of the present invention, the drug development methods utilize a team decision-making format wherein scientific staff, and regulatory, financial, and marketing personnel may contribute to the evaluation of a new drug compound. In another embodiment of the methods of the present invention, decisions concerning the future of a potential drug may be made at earlier designated timepoints in the evaluation process, and these decisions may be made based on criteria such as preclinical pharmacological and toxicological data. In a further embodiment of the present invention, the potential new drug may be assigned a risk characterization, such as a color code, which defines the extent and duration of the evaluation process.

US Patent:

20050152887, Jul 14, 2005

Filed:

Jan 14, 2004

Appl. No.:

10/757706

Inventors:

Michael Ernest - Chula Vista CA, US

International Classification:

A61K038/54

US Classification:

424094200

Abstract:

A stabilized protonic mixture having a protonic formulation (FIG. A) comprised primarily of proteins (FIG. A), enzymes and pH adjusters (FIG. A), all in specific ratios to one another; a liquid medium which, when combined to the protonic formulation, initiates activation of the amino acids within the protonic formulation; and a stabilizing component which stabilizes the amino acids during the process of their activation.